Bausch Health Companies Inc. (BHC)
Pre-market:
| Previous close | 8.74 |
| Open | 8.80 |
| Bid | 0.00 x 4000 |
| Ask | 9.71 x 3000 |
| Day's range | 8.65 - 8.93 |
| 52-week range | 5.57 - 11.46 |
| Volume | |
| Avg. volume | 2,820,612 |
| Market cap | 3.175B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 Nov 2010 |
| 1y target est | N/A |
- Reuters
Bausch wins US appeal to block Alvogen generic of diarrhea drug
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029. A Delaware federal court had determined that Alvogen subsidiary Norwich Pharmaceuticals' generic would infringe patents owned by Bausch's Salix Pharmaceuticals.
- Zacks
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Reuters
CANADA STOCKS-TSX ends flat as gold stocks drop, mood cautious ahead of rate decision
Canada's main stock index ended flat on Monday, as gains in financials and industrial stocks were offset by losses in healthcare driven by Bausch Health. Investors were cautious ahead of Wednesday's Bank of Canada interest rate decision, when the central bank is expected to hold rates steady, and release new economic growth projections. The Toronto Stock Exchange's S&P/TSX composite index was down 4.08 points, or 0.02%, at 22,260.30.
